Joyce Teng, MD, PhD is a professor in dermatology at Stanford University. She is affiliated with multiple hospitals in the area, including Lucile Salter Packard Children's Hospital (LPCH) at Stanford and Stanford Hospital and Clinics (SHC). She received her medical degree from Vanderbilt University School of Medicine and has been in practice for more than 12 years. She is one of the 5 pediatric dermatologists practicing at LPCH and one of 72 at SHC who specialize in Dermatology. She sees patients with rare genetic disorders, birthmarks, vascular anomalies and a variety of inflammatory skin diseases. She is also an experienced pediatric dermatological surgeon. Her research interests are drug discovery and novel therapy for skin disorders.

Clinical Focus

  • Pediatric Dermatology
  • Pediatric Dermatology Surgery,
  • Rheumatology Dermatology
  • Genetic Skin Disease
  • Dermatology, Epidermolysis Bullosa
  • Vascular Anomalies
  • Birthmarks

Academic Appointments

Administrative Appointments

  • Director of Pediatric Dermatology, Stanford University (2012 - Present)
  • Director of Pediatric Dermatology Fellowship, Stanford University (2012 - Present)
  • Director of Pediatric Dermatology, University of Wisconsin-Madison (2007 - 2012)

Honors & Awards

  • Mentorship Award, Women's Dermatology Society (2006)
  • William Weston Research Award, Society of Pediatric Dermatology (2009)
  • Preceptorship Award, American Society of Dermatologic Surgery (2008, 2010)
  • Teaching Award, University of Wisconsin-Madison (2012)
  • Research Award, Dermatology Foundation (2009, 2012)

Boards, Advisory Committees, Professional Organizations

  • FAAD, American Academy of Dermatology (2002 - Present)
  • Member, American Society for Dermatologic Surgery (2002 - Present)
  • Member, Society of Pediatric Dermatology (2005 - Present)
  • Member, American Academy of Pediatrics (2012 - Present)
  • Member, Women’s Dermatologic Society (2005 - Present)
  • Member, American Medical Association (2002 - Present)
  • Member, Dermatology Foundation (2007 - Present)

Professional Education

  • Medical Education:Vanderbilt University School of Medicine (2001) TN
  • Residency:Vanderbilt University Medical Center (2005) TN
  • Board Certification: Pediatric Dermatology, American Board of Dermatology (2006)
  • Fellowship:University of Colorado Health Science Center (2006) CO
  • Board Certification: Dermatology, American Board of Dermatology (2005)
  • Internship:Vanderbilt University Medical Center (2002) TN
  • Postgraduate Fellowship, Memorial Sloan-Kettering Institute, Molecular Immunology (1997)
  • PhD, Medical College of Wisconsin, Cellular Immunology (1993)
  • Medical Education:Medical College Of Wisconsin (1993) WI

Clinical Trials

  • Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS) Recruiting

    Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The simplex form is classified by skin blister development in the basal epidermis. Diacerein 1% Ointment is a topical ointment that is being developed for the treatment of EBS. Diacerein in the topical formulation is hydrolyzed to rhein in the epidermis and dermis following administration. Diacerein and rhein have been shown to inhibit the in vitro and in vivo production and activity of interleukin-1β (IL-1β) and other pro-inflammatory cytokines.The purpose of this study is to compare the efficacy of Diacerein 1% Ointment to Control Ointment when applied once-daily for 8 weeks in subjects with EBS.

    View full details

  • Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis Recruiting

    An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.

    View full details

  • Sildenafil for the Treatment of Lymphatic Malformations Recruiting

    A Phase 2 study to evaluate safety and efficacy of sildenafil taken orally to improve or resolve lymphatic malformations in children. Subjects may receive either placebo or treatment in an oral dosage with an open label extension for subjects who received placebo. The study treatment assignment will be randomized in a double blind fashion. MRI examination will evaluate change in lesion volume due to treatment. Other safety and efficacy measures will be taken through the 32-week study duration. Funding Source - FDA OOPD

    View full details

  • Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Recruiting

    The purpose of this study is to evaluate the safety and efficacy of ixekizumab in pediatric participants with moderate-to-severe plaque psoriasis.

    View full details

  • Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) Not Recruiting

    A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration. Funding Source - FDA OOPD

    Stanford is currently not accepting patients for this trial. For more information, please contact Joyce Teng, MD, PhD, 650-723-6493.

    View full details

  • Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study Not Recruiting

    Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.

    Stanford is currently not accepting patients for this trial.

    View full details

2017-18 Courses

Graduate and Fellowship Programs

All Publications

  • An Atopic Dermatitis Management Algorithm for Primary Care Providers and Assessment of Its Usefulness as a Clinical Tool. Pediatric dermatology Miyar, M. E., Brown, M., Vivar, K. L., Jablon, K., Boscardin, C., Levy, M. L., Teng, J. M., Mathes, E. F. 2017


    There is a lack of primary care provider (PCP) understanding of atopic dermatitis (AD) treatments and topical steroid use. We designed an AD management algorithm for pediatric PCPs. We hypothesized that the algorithm would improve pediatric PCPs' knowledge of AD diagnosis and management.Pediatric primary care resident and attending physicians at three residency programs were invited to participate in an electronic AD algorithm survey that contained demographic and 19 knowledge-based questions. Participants were randomized to intervention and control groups, with the intervention group receiving a short lecture and copy of our algorithm to use in an inpatient or outpatient setting for 2 months. Changes in scores between preintervention and postintervention surveys were compared.Of the 54 participants, those in the intervention group (n = 26) performed significantly better than those in the control group (n = 28) after controlling for pretest scores (β = 1.19 [95% confidence interval 0.07, 2.32], p = 0.04). The intervention group had a higher average score on the posttest knowledge questions (71% correct) than the control group (65% correct) (p = 0.06). The majority of physicians who received the algorithm agreed or strongly agreed that they liked using the algorithm.The use of a management algorithm improved physician knowledge about the diagnosis and treatment of AD and was well accepted by physicians. Use of this management algorithm may lead to better recognition and management of AD, particularly earlier recognition of and therapy for superinfection, improving treatment outcomes and quality of life for patients and families.

    View details for DOI 10.1111/pde.13157

    View details for PubMedID 28543716

  • Genetic diseases associated with an increased risk of skin cancer development in childhood. Current opinion in pediatrics Fogel, A. L., Sarin, K. Y., Teng, J. M. 2017


    Childhood skin cancers are relatively rare and may indicate an underlying genetic disorder. The increasing elucidation of genetic pathways is changing the diagnosis and management of genetic skin cancer susceptibility syndromes. In this review, we provide an overview of genetic conditions that predispose to skin cancer development in childhood and signs that providers should assess when evaluating affected individuals.In basal cell nevus syndrome (BCNS), the patched2 (PTCH2) and suppressor of fused (SUFU) genes have been implicated in disease pathogenesis. The sonic hedgehog (SHH) pathway inhibitor vismodegib was shown in a placebo-controlled phase III randomized trial to reduce the tumor burden in patients with BCNS. Epidermolysis bullosa (EB) has been classified into four major types and more than 30 subtypes based partly on specific mutations, and best clinical practice guidelines for the management of cutaneous squamous cell carcinoma in EB have been developed. Oculocutaneous albinism (OCA) has been associated with new mutations in genes named OCA5, OCA6, and OCA7, bringing to the total number of culprit genes to seven (OCA1-OCA7).Advances in our understanding of genetic conditions that predispose to childhood skin cancer include new disease classification systems, management guidelines, and treatment options.

    View details for DOI 10.1097/MOP.0000000000000514

    View details for PubMedID 28525403

  • Postzygotic Mutations in Beta-Actin are Associated with Becker's Nevus and Becker's Nevus Syndrome. journal of investigative dermatology Cai, E. D., Sun, B. K., Chiang, A., Rogers, A., Bernet, L., Cheng, B., Teng, J., Rieger, K. E., Sarin, K. Y. 2017

    View details for DOI 10.1016/j.jid.2017.03.017

    View details for PubMedID 28347698

  • Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome Development of a Basal Cell Nevus Syndrome Patient Registry JAMA DERMATOLOGY Solis, D. C., Kwon, G. P., Ransohoff, K. J., Li, S., Chahal, H. S., Ally, M. S., Peters, M. A., Schmitt-Burr, K., Lindgren, J., Bailey-Healy, I., Teng, J. M., Epstein, E. H., Tang, J. Y. 2017; 153 (2): 189-192
  • Use of topical sirolimus in the management of multiple familial trichoepitheliomas. Dermatologic therapy Tu, J. H., Teng, J. M. 2017


    The management of trichoepitheliomas is challenging, especially in children. This challenge is exemplified in patients with multiple trichoepitheliomas who present with progression of lesion count and size despite treatment with current strategies, including CO2 laser and surgery. We present the novel use of topical 1% sirolimus cream in two siblings with multiple facial trichoepitheliomas; one was treated with a combination of CO2 laser ablation and topical sirolimus, and the other was treated with topical sirolimus alone. Both siblings had a reduction in the growth of new lesions with no reported side effects. This is the first report demonstrating that topical sirolimus, either in combination with CO2 laser or alone, can be a promising treatment for trichoepitheliomas.

    View details for DOI 10.1111/dth.12458

    View details for PubMedID 28133868

  • Risk Factors for Basal Cell Carcinoma Among Patients With Basal Cell Nevus Syndrome: Development of a Basal Cell Nevus Syndrome Patient Registry. JAMA dermatology Solis, D. C., Kwon, G. P., Ransohoff, K. J., Li, S., Chahal, H. S., Ally, M. S., Peters, M. A., Schmitt-Burr, K., Lindgren, J., Bailey-Healy, I., Teng, J. M., Epstein, E. H., Tang, J. Y. 2016


    Patients with basal cell nevus syndrome (BCNS) have a greater risk of developing numerous basal cell carcinomas (BCCs). Risk factors influencing the wide variation in tumor burden are poorly understood.To describe the burden of BCCs in patients with BCNS in the United States and identify potential risk factors for BCCs.Prospective clinical registry with data collected from September 2014 to March 2016. Participants were recruited from a mailing list of patients with BCNS at Children's Hospital Oakland Research Institute and Basal Cell Carcinoma Nevus Syndrome Life Support Network. Patients of all ages with a diagnosis of BCNS were eligible for enrollment. Participants completed a clinical questionnaire on their disease characteristics and risk factors.Number of BCCs in the past 2 years and over lifetime (disease burden), risk factors for BCCs.A consecutive sample of the first 141 participants was included (34% [100 of 297] response rate from paper survey, 23% [41 of 179] from online survey; 85 [60%] female; mean age at start of study, 53 [range, 8-83] years; 131 [93%] white). In the previous 2 years, participants reported a mean of 25 BCCs (median, 11; range, 0-250). Over their lifetime, participants reported a mean of 257 BCCs (median, 160; range, 0-2200). Univariate analysis identified age (odds ratio [OR], 1.05; 95% CI, 1.03-1.07; P < .001), number of sunburns (OR, 1.05; 95% CI, 1.00-1.10; P = .047), and history of radiation exposure (OR, 2.26; 95% CI, 1.02-5.03; P = .046) as potential risk factors for lifetime BCC severity. On multivariate analysis, only age (OR, 1.04; 95% CI, 1.02-1.07; P < .001) and number of sunburns (OR, 1.06; 95% CI, 1.00-1.11; P = .04) were statistically significant. In our adjusted models, BCC burden increased by 4% per year of age and by 6% per number of sunburns.Patients with BCNS have a high burden of BCCs. Age and number of sunburns were significantly associated with the severity of lifetime BCC. Further interventions to prevent and treat BCCs in patients with BCNS are needed.

    View details for DOI 10.1001/jamadermatol.2016.4347

    View details for PubMedID 27902821

  • Cutaneous Malignancies in Pediatric Solid Organ Transplant Recipients PEDIATRIC DERMATOLOGY Fogel, A. L., Miyar, M., Teng, J. M. 2016; 33 (6): 585-593


    Pediatric organ transplant recipients (POTRs) are at risk of developing malignancies due to a combination of immunosuppression, impaired DNA damage repair, and infection with oncogenic viruses. The most commonly developed malignancies in this population are skin cancers, which include nonmelanoma skin cancer, melanoma, Kaposi's sarcoma, and anogenital carcinoma. The literature shows that skin cancers account for 13% to 55% of all cancers that occur after transplantation. Given the increasing number and life expectancy of POTRs, prevention and management of skin cancer in these patients is essential, but there is a substantial knowledge gap in our understanding of the differences in skin cancer development, prevention, and management between POTRs and adult organ transplant recipients (AOTRs), for whom more data are available. Substantial differences have been observed in the patterns of malignancy development between POTRs and AOTRs, and data specific to pediatric populations are needed. The objective of this review is to provide updated information on posttransplantation skin cancer development in POTRs, including epidemiologic research on transplant patients and disease development, medication management, surveillance, and education efforts.

    View details for DOI 10.1111/pde.12941

    View details for Web of Science ID 000389132200021

    View details for PubMedID 27470071

  • Direct-to-consumer teledermatology services for pediatric patients: Room for improvement. Journal of the American Academy of Dermatology Fogel, A. L., Teng, J., Sarin, K. Y. 2016; 75 (5): 887-888


    Direct-to-consumer teledermatology is radically changing the way some patients obtain dermatologic care. Many direct-to-consumer teledermatology services offer care to patients younger than 18 years, but policies and standards are nonuniform. For pediatric patients, direct-to-consumer teledermatology is a substantial departure from in-person care. More consensus, standards, and guidelines are necessary.

    View details for DOI 10.1016/j.jaad.2016.08.002

    View details for PubMedID 27614530

  • Novel Treatment Using Cimetidine for Erythropoietic Protoporphyria in Children JAMA DERMATOLOGY Tu, J. H., Sheu, S. L., Teng, J. M. 2016; 152 (11): 1258-1261


    Erythropoietic protoporphyria (EPP) is a rare hereditary disease of heme biosynthesis that manifests as severe photosensitivity and hepatotoxicity. There have been no effective treatments to date. Cimetidine has been shown to inhibit heme biosynthesis and results in symptomatic improvement in patients with acute intermittent porphyria (AIP) and porphyria cutanea tarda (PCT). There is only 1 report in the literature describing the use of cimetidine in the effective treatment of an adult patient with EPP.To describe the successful use of cimetidine in pediatric patients with EPP.Retrospective medical record review carried out in a pediatric dermatology practice at an academic institution of patients diagnosed with EPP who were younger than 18 years and treated with systemic cimetidine in the past 3 years.Systemic cimetidine.Resolution of skin photodamage was evaluated on clinical examination. Subjective measures including tolerability to sun exposure, ability to participate in outdoor activities, and objective evaluation including serum erythrocyte protoporphyrin levels and liver function tests following treatment were assessed.All 3 cases reported a rapid reduction in photosensitivity within weeks following initiation of systemic therapy. Their skin photodamage were also improved or resolved completely on subsequent examination. Laboratory study results also revealed reduction in serum erythrocyte protoporphyrin levels and improved liver function. None of the patients have reported any adverse effects of the systemic treatment after more than 2 years of treatment.Children with EPP currently have limited therapeutic options and experience substantial disease impact on their quality of life. This is the first case series demonstrating that cimetidine, a readily available oral medication, can be a promising treatment for children with EPP.

    View details for DOI 10.1001/jamadermatol.2016.2303

    View details for Web of Science ID 000388234700016

    View details for PubMedID 27410690

  • Sclerotherapy for lymphatic malformations of the head and neck in the pediatric population. Journal of neurointerventional surgery Tu, J. H., Do, H. M., Patel, V., Yeom, K. W., Teng, J. M. 2016


    Sclerotherapy is one of the most commonly used minimally invasive interventions in the treatment of macrocystic lymphatic malformations (LMs). Several different sclerosing agents and injection protocols have been reported in the literature, each with varying degrees of success. The safety and efficacy of the treatments have not been evaluated comparatively in the pediatric population.Chart review of pediatric patients with macrocystic/mixed head and neck LMs who underwent sclerotherapy using OK-432, doxycycline, or ethanolamine oleate at Lucile Packard Children's Hospital at Stanford during 2000-2014. Clinical evaluation and radiographic imaging were reviewed to assess lesion characteristics and response to sclerotherapy following each treatment session. The post-intervention clinical response was categorized as excellent, good, fair, or poor.Among the 41 pediatric cases reviewed, 10 patients were treated with OK-432, 19 patients received doxycycline, and 12 patients received ethanolamine. In univariate analysis, different sclerosants had similar effectiveness after the first injection and final clinical outcome (p=0.5317). In multivariate analysis controlling for disease severity stage as well as disease characteristics (macrocystic vs mixed subtypes), different sclerosants also had similar effectiveness after the first injection (p=0.1192). Radiologic analysis indicated an 84.5% average volume reduction, with similar effectiveness between the different sclerosants (p=0.9910).In this series of LM cases treated at Stanford, we found that doxycycline, OK-432, and ethanolamine oleate sclerotherapy appear to have a similar safety and efficacy profile in the treatment of macrocystic and mixed LMs of the head and neck in the pediatric population.

    View details for DOI 10.1136/neurintsurg-2016-012660

    View details for PubMedID 27707871

  • Pediatric dermatology: advancement in management and targeted therapy. Current opinion in pediatrics Teng, J. M. 2016; 28 (4): 454-455

    View details for DOI 10.1097/MOP.0000000000000385

    View details for PubMedID 27386967

  • Advancement in management of epidermolysis bullosa. Current opinion in pediatrics Cohn, H. I., Teng, J. M. 2016; 28 (4): 507-516


    Epidermolysis bullosa is a hereditary skin disorder characterized by skin fragility. However, the disease can manifest in many different organ systems, therefore children born with epidermolysis bullosa may have life long, complex medical needs. In this review, we will use a system-based approach to highlight important aspects of disease management and recent advancements in each of the areas. In addition, we will overview some of the cutting edge therapeutic developments in epidermolysis bullosa.Recent advancements in supportive care of epidermolysis bullosa with focus on wound, pain, pruritus and nutrition status were discussed. Clinical surveillance and complication prevention are critical to improve clinical outcomes. Generalized epidermolysis bullosa is a systemic disease with increased morbidity and mortality; therefore, complex care using a multidisciplinary approach will provide the greatest benefits for patients. Current targeted treatments for epidermolysis bullosa aim at restoring the skin integrity using protein, cell, and gene therapies.Improvement in care of epidermolysis bullosa in recent years results from keen clinical observation, novel molecular targeting, and the embracement of translational research.

    View details for DOI 10.1097/MOP.0000000000000380

    View details for PubMedID 27386970

  • RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndrome. American journal of medical genetics. Part A Macmurdo, C. F., Wooderchak-Donahue, W., Bayrak-Toydemir, P., Le, J., Wallenstein, M. B., Milla, C., Teng, J. M., Bernstein, J. A., Stevenson, D. A. 2016; 170 (6): 1450-1454


    Germline mutations in RASA1 are associated with capillary malformation-arteriovenous malformation (CM-AVM) syndrome. CM-AVM syndrome is characterized by multi-focal capillary malformations and arteriovenous malformations. Lymphatic anomalies have been proposed as part of the phenotype. Intrafamilial variability has been reported, suggesting modifiers and somatic events. The objective of the study was to identify somatic RASA1 "second hits" from vascular malformations associated with CM-AVM syndrome, and describe phenotypic variability. Participants were examined and phenotyped. Genomic DNA was extracted from peripheral blood on all participants. Whole-exome sequencing was performed on the proband. Using Sanger sequencing, RASA1 exon 8 was PCR-amplified to track the c.1248T>G, p.Tyr416X germline variant through the family. A skin biopsy of a capillary malformation from the proband's mother was also obtained, and next-generation sequencing was performed on DNA from the affected tissue. A familial germline heterozygous novel pathogenic RASA1 variant, c.1248T>G (p.Tyr416X), was identified in the proband and her mother. The proband had capillary malformations, chylothorax, lymphedema, and overgrowth, while her affected mother had only isolated capillary malformations. Sequence analysis of DNA extracted from a skin biopsy of a capillary malformation of the affected mother showed a second RASA1 somatic mutation (c.2245C>T, p.Arg749X). These results and the extreme variable expressivity support the hypothesis that somatic "second hits" are required for the development of vascular anomalies associated with CM-AVM syndrome. In addition, the phenotypes of the affected individuals further clarify that lymphatic manifestations are also part of the phenotypic spectrum of RASA1-related disorders. © 2016 Wiley Periodicals, Inc.

    View details for DOI 10.1002/ajmg.a.37613

    View details for PubMedID 26969842

  • Systemic Hyalinosis With Heterozygous CMG2 Mutations: A Case Report and Review of Literature AMERICAN JOURNAL OF DERMATOPATHOLOGY Rahvar, M., Teng, J., Kim, J. 2016; 38 (5): E60-E63


    Juvenile hyaline fibromatosis (JHF) is a rare autosomal recessive disorder characterized by hyalinizing fibrosis of the skin and internal organs. Clinical features include multiple papular skin lesions, gingival hyperplasia, joint contractures, and osteolytic bone lesions. The systemic variant of JHF, known as infantile systemic hyalinosis (ISH), has an early onset and poor prognosis. Histological examination of cutaneous lesions shows bland-appearing fibroblasts within amorphous eosinophilic hyaline depositions. JHF and infantile systemic hyalinosis form a clinical spectrum with higher mortality that is typically observed in systemic cases. Here, the authors present a case of systemic hyalinosis with a heterozygous mutation in CMG2 that resulted in improved survival.

    View details for Web of Science ID 000374832500003

    View details for PubMedID 26885603

  • Social Media Use in Pediatric Dermatology PEDIATRIC DERMATOLOGY Fogel, A. L., Teng, J. M. 2016; 33 (2): E131-E133

    View details for DOI 10.1111/pde.12763

    View details for Web of Science ID 000373067800025

  • A Survey to Assess Perceived Differences in Referral Pathways to Board-Certified Pediatric Dermatologists. Pediatric dermatology Fogel, A. L., Teng, J. M. 2015; 32 (6): e314-315


    This study surveyed all U.S. board-certified pediatric dermatologists to determine referral pathways to the specialty; we obtained a 48% (108/226) response rate. Significantly higher self-referral rates were found in private practice than in academic settings, and higher referral rates from specialist and generalist physicians were observed in academic practice. The substantial differences found in this preliminary study indicate that triage inefficiency may be occurring, and further study to investigate the causes for referral differences and their effect on clinical outcomes is needed.

    View details for DOI 10.1111/pde.12703

    View details for PubMedID 26446294

  • A Survey to Assess Perceived Differences in Referral Pathways to Board-Certified Pediatric Dermatologists PEDIATRIC DERMATOLOGY Fogel, A. L., Teng, J. M. 2015; 32 (6)

    View details for DOI 10.1111/pde.12703

    View details for Web of Science ID 000365526000026

    View details for PubMedID 26446294

  • Acantholytic Dyskeratotic Epidermal Nevus. JAMA dermatology Akinshemoyin Vaughn, O., Hinshaw, M. A., Teng, J. M. 2015; 151 (11): 1259-1260

    View details for DOI 10.1001/jamadermatol.2015.1663

    View details for PubMedID 26131939

  • The US Pediatric Dermatology Workforce: An Assessment of Productivity and Practice Patterns PEDIATRIC DERMATOLOGY Fogel, A. L., Teng, J. M. 2015; 32 (6): 825-829


    Pediatric dermatology has always played an important role in children's healthcare, but there has been a shortage of pediatric dermatologists nationwide for more than a decade, and few metrics of productivity and practice patterns exist. This study sought to provide insight into these and other factors of the pediatric dermatology workforce.Electronic surveys were distributed to all 226 U.S. board-certified pediatric dermatologists.A total of 108/226 (48%) of the electronic surveys were returned. Sixty percent of respondents were employed full- or part-time in academic environments and 81% were salaried. Respondents reported that children constituted 79.5% of their practice, and the average respondent spent 3.8 days/week treating 92.6 patients, considerably lower than the 136.3 patients/week that the average general dermatologist sees. The academic practice environment was associated with children constituting a larger proportion of the practice (p < 0.001), fewer patients seen per week (85.9, p < 0.001), and longer median new patient wait times (60 vs 15 days) than in other practice environments. Private practitioners saw significantly more patients per week than those in academic environments (112.7, p = 0.005). Male and female practitioners reported approximately equal patient care days per week, similar wait times, and similar proportions of children in their practices.This assessment revealed productivity and practice pattern differences between the various pediatric dermatology practice environments and between pediatric and general dermatology. This study provides important information for workforce planning and care availability assessments and baseline information for future studies.

    View details for DOI 10.1111/pde.12680

    View details for Web of Science ID 000365526000042

    View details for PubMedID 26391633

  • Pediatric Lichen Sclerosus: A Review of the Epidemiology and Treatment Options. Pediatric dermatology Tong, L. X., Sun, G. S., Teng, J. M. 2015; 32 (5): 593-599


    Lichen sclerosus (LS) is a rare, chronic, inflammatory disease of the skin that primarily affects postmenopausal women but may occur in men and children as well. Approximately 7% to 15% of cases are believed to occur in children. The epidemiologic data for LS have been limited and treatment options are not well studied, particularly in children. We reviewed new developments available in the current literature on the epidemiology and management of LS for children.

    View details for DOI 10.1111/pde.12615

    View details for PubMedID 25940739

  • Treatment of complex periorbital venolymphatic malformation in a neonate with a combination therapy of sirolimus and prednisolone. Dermatologic therapy Kim, D., Benjamin, L., Wysong, A., Hovsepian, D., Teng, J. 2015; 28 (4): 218-221


    Venolymphatic malformations (VLMs) are vascular anomalies consisting of both veins and lymph vessels. A 2-week-old newborn presented with large VLMs on the left forehead, temple, preauricular area, and orbit. Patient was at imminent risk for permanent vision loss due to a localized mass effect. Surgical excision or debulking was contraindicated due to its complexity and proximity to the left eye, and the patient failed to respond to the sildenafil treatment and sclerotherapy. Patient was subsequently started on oral sirolimus 0.8 mg/m(2) twice daily in combination with prednisolone 2 mg/kg daily. The patient had an excellent therapeutic outcome for 7 months with complete preservation of vision before treatment was discontinued. However, 2 months after the medical treatments were discontinued, her VLM rebounded. She responded to the combination therapy again after a failed treatment with the mTOR inhibitor alone. This case demonstrates that the sirolimus and prednisolone combination therapy could be beneficial for treatment of complex VLM intractable to other treatments.

    View details for DOI 10.1111/dth.12208

    View details for PubMedID 25753853

  • Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Fogel, A. L., Hill, S., Teng, J. M. 2015; 72 (5): 879-889


    Significant developments in the use of mammalian target of rapamycin (mTOR) inhibitors (mTORIs) as immunosuppressant and antiproliferative agents have been made. Recent advances in the understanding of the mTOR signaling pathway and its downstream effects on tumorigenesis and vascular proliferation have broadened the clinical applications of mTORIs in many challenging disorders such as tuberous sclerosis complex, pachyonychia congenita, complex vascular anomalies, and inflammatory dermatoses. Systemic mTORI therapy has shown benefits in these areas, but is associated with significant side effects that sometimes necessitate drug holidays. To mitigate the side effects of systemic mTORIs for dermatologic applications, preliminary work to assess the potential of percutaneous therapy has been performed, and the evidence suggests that percutaneous delivery of mTORIs may allow for effective long-term therapy while avoiding systemic toxicities. Additional large placebo-controlled, double-blinded, randomized studies are needed to assess the efficacy, safety, duration, and tolerability of topical treatments. The objective of this review is to provide updated information on the novel use of mTORIs in the management of many cutaneous disorders.

    View details for DOI 10.1016/j.jaad.2015.01.014

    View details for Web of Science ID 000353118400028

    View details for PubMedID 25769191

  • Pediatric Teledermatology: A Survey of Usage, Perspectives, and Practice PEDIATRIC DERMATOLOGY Fogel, A. L., Teng, J. M. 2015; 32 (3): 363-368


    Pediatric dermatology is one of the smallest subspecialties, and expanding the availability of care is of great interest. Teledermatology has been proposed as a way to expand access and improve care delivery, but no current assessment of pediatric teledermatology exists. The objective of the current study was to assess usage and perspectives on pediatric teledermatology. Surveys were distributed electronically to all 226 board-certified U.S. pediatric dermatologists; 44% (100/226) responded. Nearly all respondents (89%) have experience with teledermatology. Formal teledermatology reimbursement success rates have increased to 35%. Respondents were positive about teledermatology's present and future prospects, and 41% want to use teledermatology more often, although they viewed teledermatology as somewhat inferior to in-person care regarding accuracy of diagnosis and appropriation of management plans. Significant differences were found between formal teledermatology users and nonusers in salary structure, practice environment, sex, and region. Substantial increases in pediatric teledermatology have occurred in the last 5 to 10 years, and there remains cause for optimism for teledermatology's future. Concerns about diagnostic confidence and care quality indicate that teledermatology may be best for care of patients with characteristic clinical presentations or management of patients with established diagnoses.

    View details for DOI 10.1111/pde.12533

    View details for Web of Science ID 000354820500035

    View details for PubMedID 25691131

  • Treatment of keratitis-ichthyosis-deafness (KID) syndrome in children: a case report and review of the literature DERMATOLOGIC THERAPY Patel, V., Sun, G., Dickman, M., Phuong Khuu, P., Teng, J. M. 2015; 28 (2): 89-93

    View details for DOI 10.1111/dth.12192

    View details for Web of Science ID 000352630800010

  • Treatment of keratitis-ichthyosis- deafness (KID) syndrome in children: a case report and review of the literature. Dermatologic therapy Patel, V., Sun, G., Dickman, M., Khuu, P., Teng, J. M. 2015; 28 (2): 89-93


    Keratitis-ichthyosis-deafness (KID) syndrome is a rare hereditary cornification disorder resulting from mutations in connexin 26, a protein important for intercellular communication. In addition to the characteristic clinical triad of congenital bilateral sensorineural hearing loss, keratitis, and erythrokeratoderma, affected individuals also suffer from chronic bacterial and fungal infections and have an increased risk of benign and malignant cutaneous tumors. Treatments with antibiotics, antifungals, and systemic retinoids have been reported with variable response. Ocular and skeletal toxicity from prolonged exposure to systemic retinoids is a major concern especially in children. We report a case of a 7-year-old boy with KID syndrome complicated by frequent infections who responded well to acitretin 0.5-1.0 mg/kg/day. The patient had significant improvement of the hyperkeratosis on the scalp, trunk, and extremities within 4 weeks after initiating treatment. The patient has been on treatment for over a year without notable ocular, skeletal, or laboratory side effects. A review of the literature focusing on therapeutic options for KID syndrome and concerns about safety and tolerability is presented.

    View details for DOI 10.1111/dth.12192

    View details for PubMedID 25546246

  • Medicaid acceptance among pediatric dermatologists JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Fogel, A. L., Teng, J. M. 2015; 72 (1): 191-193

    View details for DOI 10.1016/j.jaad.2014.09.034

    View details for Web of Science ID 000346404500054

    View details for PubMedID 25497924

  • Scabies infection in a neonate. journal of pediatrics Kim, D., Teng, J. 2014; 165 (6): 1266-1266 e1

    View details for DOI 10.1016/j.jpeds.2014.07.061

    View details for PubMedID 25217198

  • Proceedings of the Inaugural Pediatric Dermatology Research Alliance (PeDRA) Conference JOURNAL OF INVESTIGATIVE DERMATOLOGY Siegel, D. H., Choate, K. A., Drolet, B. A., Frieden, I. J., Rittenberg, S., Teng, J. M., Tom, W. L., Williams, M. L., Eichenfield, L. F., Paller, A. S. 2014; 134 (11): 2671-2674
  • Channelopathy: a novel mutation in the SCN9A gene causes insensitivity to pain and autonomic dysregulation BRITISH JOURNAL OF DERMATOLOGY Bartholomew, F., Lazar, J., Marqueling, A., Lee-Messer, C., Jaradeh, S., Teng, J. M. 2014; 171 (5): 1268-1270

    View details for DOI 10.1111/bjd.13096

    View details for Web of Science ID 000346600000038

    View details for PubMedID 24813348

  • Proceedings of the Inaugural Pediatric Dermatology Research Alliance (PeDRA) conference. journal of investigative dermatology Siegel, D. H., Choate, K. A., Drolet, B. A., Frieden, I. J., Rittenberg, S., Teng, J. M., Tom, W. L., Williams, M. L., Eichenfield, L. F., Paller, A. S. 2014; 134 (11): 2671-2674

    View details for DOI 10.1038/jid.2014.227

    View details for PubMedID 25318428

  • Dermatologic and Dental Aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements JAMA DERMATOLOGY Teng, J. M., Cowen, E. W., Wataya-Kaneda, M., Gosnell, E. S., Witman, P. M., Hebert, A. A., Mlynarczyk, G., Soltani, K., Darling, T. N. 2014; 150 (10): 1095-1101
  • Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. JAMA dermatology Teng, J. M., Cowen, E. W., Wataya-Kaneda, M., Gosnell, E. S., Witman, P. M., Hebert, A. A., Mlynarczyk, G., Soltani, K., Darling, T. N. 2014; 150 (10): 1095-1101


    The 2012 International Tuberous Sclerosis Complex Clinical Consensus Conference was convened to update the last consensus statement in 1998. Skin and dental lesions are common in tuberous sclerosis complex (TSC) and are a frequent concern for patients. Recognition of these lesions is imperative for early diagnosis, given the treatment advances that may improve patient outcomes.To detail recommendations for the diagnosis, surveillance, and management of skin and dental lesions in TSC.The TSC Dermatology and Dentistry Subcommittee, 1 of 12 subcommittees, reviewed the relevant literature from 1997 to 2012.A consensus on skin and dental issues was achieved within the Dermatology and Dentistry Subcommittee before recommendations were presented, discussed, and agreed on in a group meeting of all subcommittees from June 14 to 15, 2012.Skin and dental findings comprise 4 of 11 major features and 3 of 6 minor features in the diagnostic criteria. A definite diagnosis of TSC is defined as the presence of at least 2 major features or 1 major and 2 or more minor features; in addition, a pathological mutation in TSC1 or TSC2 is diagnostic. Skin and oral examinations should be performed annually and every 3 to 6 months, respectively. Intervention may be indicated for TSC skin or oral lesions that are bleeding, symptomatic, disfiguring, or negatively affecting function. Options presented include surgical excision, laser(s), or use of a mammalian target of rapamycin inhibitor.

    View details for DOI 10.1001/jamadermatol.2014.938

    View details for PubMedID 25029267

  • An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. Journal of the American Academy of Dermatology Danial, C., Tichy, A. L., Tariq, U., Swetman, G. L., Khuu, P., Leung, T. H., Benjamin, L., Teng, J., Vasanawala, S. S., Lane, A. T. 2014; 70 (6): 1050-1057


    Lymphatic malformations can be challenging to treat. Mainstay interventions including surgery and sclerotherapy are invasive and can result in local recurrence and complications.We sought to assess the effect of 20 weeks of oral sildenafil on reducing lymphatic malformation volume and symptoms in children.Seven children (4 boys, 3 girls; ages 13-85 months) with lymphatic malformations were given oral sildenafil for 20 weeks in this open-label study. The volume of the lymphatic malformation was calculated blindly using magnetic resonance imaging performed before and after 20 weeks of sildenafil. Lymphatic malformations were assessed clinically on weeks 4, 12, 20, and 32. Both the physician and parents evaluated the lymphatic malformation in comparison with baseline.Four subjects had a lymphatic malformation volume decrease (1.0%-31.7%). In 2 subjects, despite a lymphatic malformation volume increase (1.1%-3.7%), clinical improvement was noted while on sildenafil. One subject had a 29.6% increase in lymphatic malformation volume and no therapeutic response. Lymphatic malformations of all 6 subjects who experienced a therapeutic response on sildenafil softened and became easily compressible. Adverse events were minimal.A randomized controlled trial will be necessary to verify the effects of sildenafil on lymphatic malformations.Sildenafil can reduce lymphatic malformation volume and symptoms in some children.

    View details for DOI 10.1016/j.jaad.2014.02.005

    View details for PubMedID 24656411

  • Xanthoma striatum palmare associated with nonsyndromic paucity of the interlobular bile ducts. Cutis Fett, N., Teng, J. M. 2014; 93 (5): E6-8

    View details for PubMedID 24897150

  • Somatic HRAS p.G12S Mutation Causes Woolly Hair and Epidermal Nevi JOURNAL OF INVESTIGATIVE DERMATOLOGY Levinsohn, J. L., Teng, J., Craiglow, B. G., Loring, E. C., Burrow, T. A., Mane, S. S., Overton, J. D., Lifton, R. P., McNiff, J. M., Lucky, A. W., Choate, K. A. 2014; 134 (4): 1149-1152

    View details for DOI 10.1038/jid.2013.430

    View details for Web of Science ID 000333197500042

    View details for PubMedID 24129065

  • An investigational study to evaluate sildenafil for the treatment of lymphatic malformations International Investigative Dermatology Meeting Danial, C., Tichy, A., Tariq, U., Swetman, G. L., Khuu, P., Leung, T., Teng, J., VASANAWALA, S., Lane, A. NATURE PUBLISHING GROUP. 2013: S175–S175
  • Familial Urticaria Pigmentosa: Report of a Family and Review of the Role of KIT Mutations AMERICAN JOURNAL OF DERMATOPATHOLOGY Fett, N. M., Teng, J., Longley, B. J. 2013; 35 (1): 113-116


    Cutaneous mastocytosis is a rare clinically heterogeneous disorder characterized by mast cell infiltration. Mastocytosis affects both children and adults and has been reported to occur in families. Recent data suggest that mutations in the c-kit proto-oncogene are causative of mastocytosis not only in adults but in children and familial cases as well; however, mutation analysis other than D816V is not widely available, making detection of causative mutations problematic. We present the case of a 33-year-old man with a 30-year history of persistent urticaria pigmentosa and his 2 affected children. Sequencing of KIT exons 8, 10, 11, and 17 was carried out on a skin biopsy specimen and mucosal swabs of the incident case and was negative for known KIT mutations. Additional work-up was deferred by the family. Presentation of this familial case of urticaria pigmentosa demonstrates the complexity of genetic evaluation in clinical settings. It suggests that mutations other than those reported in exons 8, 10, 11, and 17 may also result in familial mastocytosis. Presentation of this case also allows for review of the mechanism of action of causative KIT mutations and the recent literature supporting KIT mutations in childhood and familial mastocytosis.

    View details for DOI 10.1097/DAD.0b013e31826330bf

    View details for Web of Science ID 000314103600024

    View details for PubMedID 22892471

  • Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatric Neurology Northrup, H., Krueger, D., International Tuberous Sclerosis Complex Consensus Group. 2013; 49 (4): 243-54.
  • Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatric Neurology Krueger, D., Northrup, H., International Tuberous Sclerosis Complex Consensus Group. 2013; 49 (4): 255-65
  • Dermatofibrosarcoma Protuberans in Children: an Update on the Diagnosis and Treatment PEDIATRIC DERMATOLOGY Kornik, R. I., Muchard, L. K., Teng, J. M. 2012; 29 (6): 707-713


    Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor of low grade malignant potential. Although rare, pediatric cases pose a particular challenge in diagnosis and management. In children, the clinical appearance may be heterogeneous and a high index of suspicion is necessary to avoid delays in diagnosis which can lead to further morbidity. Histologic examination, often with the use of appropriate immunostains, is necessary for diagnosis. Advances in the understanding of the molecular genetics of DFSP have led to further diagnostic and therapeutic modalities. DFSP is thought to result from a translocation between platelet-derived growth factor beta (PDGFB, 22q13.1) and type 1 collagen (COL1A1, 17q21≈22) leading to a fusion protein (PDGFB) which stimulates the PDGF receptor. Detection of this translocation in tissue via PCR or fluorescence in situ hybridization (FISH) can be helpful in difficult cases. While surgery with wide local excision or Mohs micrographic surgery is the mainstay of treatment, the use of targeted therapy with imatanib mesylate shows promise in large or unresectable tumors. Knowledge of the clinical features, histology, genetics, and treatment options is important for successful management of these tumors.

    View details for DOI 10.1111/j.1525-1470.2012.01767.x

    View details for Web of Science ID 000310565500001

    View details for PubMedID 22780227

  • Effective Topical Combination Therapy for Treatment of Lichen Striatus in Children: A Case Series and Review JOURNAL OF DRUGS IN DERMATOLOGY Youssef, S. M., Teng, J. M. 2012; 11 (7): 872-875


    Lichen striatus (LS) is an uncommon linear dermatosis that is primarily seen in children from 4 months to 15 years of age. While some of these eruptions are asymptomatic, others can be quite pruritic. In darker-skinned individuals, post-inflammatory hypopigmentation can be significant and may provide a cause for concern for the patients and/or their parents. In our case series of 4 patients, we observed rapid resolution of LS by combining a topical retinoid with a topical steroid. To our knowledge, this is the first report of successful treatment with this kind of combination therapy in the English literature. The patients not only achieved satisfying cosmesis, but also complete resolution of their pruritus. The most common side effect of topical tazarotene is localized irritation at treatment sites, but the patients in this particular series tolerated the treatment well.

    View details for Web of Science ID 000306164100018

    View details for PubMedID 22777233

  • Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise EXPERIMENTAL DERMATOLOGY Chamcheu, J. C., Wood, G. S., Siddiqui, I. A., Syed, D. N., Adhami, V. M., Teng, J. M., Mukhtar, H. 2012; 21 (7): 481-489


    Hereditary keratin disorders of the skin and its appendages comprise a large group of clinically heterogeneous disfiguring blistering and ichthyotic diseases, primarily characterized by the loss of tissue integrity, blistering and hyperkeratosis in severely affected tissues. Pathogenic mutations in keratins cause these afflictions. Typically, these mutations in concert with characteristic features have formed the basis for improved disease diagnosis, prognosis and most recently therapy development. Examples include epidermolysis bullosa simplex, keratinopathic ichthyosis, pachyonychia congenita and several other tissue-specific hereditary keratinopathies. Understanding the molecular and genetic events underlying skin dysfunction has initiated alternative treatment approaches that may provide novel therapeutic opportunities for affected patients. Animal and in vitro disease modelling studies have shed more light on molecular pathogenesis, further defining the role of keratins in disease processes and promoting the translational development of new gene and pharmacological therapeutic strategies. Given that the molecular basis for these monogenic disorders is well established, gene therapy and drug discovery targeting pharmacological compounds with the ability to reinforce the compromised cytoskeleton may lead to promising new therapeutic strategies for treating hereditary keratinopathies. In this review, we will summarize and discuss recent advances in the preclinical and clinical modelling and development of gene, natural product, pharmacological and protein-based therapies for these disorders, highlighting the feasibility of new approaches for translational clinical therapy.

    View details for DOI 10.1111/j.1600-0625.2012.01534.x

    View details for Web of Science ID 000305508500001

    View details for PubMedID 22716242

  • Treatment of Recalcitrant Excessive Granulation Tissue with Photodynamic Therapy in an Eight-Year-Old Patient with Focal Dermal Hypoplasia Syndrome PEDIATRIC DERMATOLOGY Liu, J., Hsu, P. T., Vanderwielen, B. A., Teng, J. M. 2012; 29 (3): 324-326


    We report a pediatric patient with focal dermal hypoplasia syndrome who developed painful excessive granulation tissue refractory to traditional medical and surgical therapies. Complete response was achieved rapidly with a combination of photodynamic therapy and intralesional steroid injections. The patient has remained in remission for longer than a year.

    View details for DOI 10.1111/j.1525-1470.2011.01436.x

    View details for Web of Science ID 000304139900018

    View details for PubMedID 21995324

  • Chemically defined conditions for human iPSC derivation and culture NATURE METHODS Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., Wagner, R., Lee, G. O., Antosiewicz-Bourget, J., Teng, J. M., Thomson, J. A. 2011; 8 (5): 424-U76


    We re-examine the individual components for human embryonic stem cell (ESC) and induced pluripotent stem cell (iPSC) culture and formulate a cell culture system in which all protein reagents for liquid media, attachment surfaces and splitting are chemically defined. A major improvement is the lack of a serum albumin component, as variations in either animal- or human-sourced albumin batches have previously plagued human ESC and iPSC culture with inconsistencies. Using this new medium (E8) and vitronectin-coated surfaces, we demonstrate improved derivation efficiencies of vector-free human iPSCs with an episomal approach. This simplified E8 medium should facilitate both the research use and clinical applications of human ESCs and iPSCs and their derivatives, and should be applicable to other reprogramming methods.

    View details for DOI 10.1038/NMETH.1593

    View details for Web of Science ID 000289987100021

    View details for PubMedID 21478862

  • A Case of Sclerodermatous Graft-versus-Host Disease Responsive to Imatinib Therapy PEDIATRIC DERMATOLOGY Lazar, J., Poonawalla, T., Teng, J. M. 2011; 28 (2): 172-175


    Sclerodermatous graft-versus-host disease (sGVHD) is a rare, late complication of hematopoietic cell transplantation. Classified as a variant of chronic graft-versus-host disease, sGVHD is thought to be predominantly an immune-mediated response characterized by aberrant T-cell function and dysregulation of tyrosine kinase cascades. Recently, the profibrotic cytokine transforming growth factor B and stimulatory autoantibodies against the platelet-derived growth factor receptor have been implicated in the pathogenesis of sGVHD. Treatment of sGVHD remains disappointing and largely limited by systemic side effects. Imatinib mesylate is a small molecule tyrosine kinase inhibitor that has been shown to selectively inhibit both the platelet-derived growth factor receptor and transforming growth factor-β signaling pathways. We report a case of sGVHD in a pediatric patient that was resistant to traditional therapy but showed improvement in cutaneous symptoms following daily treatment with 400 mg of imatinib mesylate. Due to its favorable side-effect profile, specificity for molecular pathways deranged in sGVHD and proven efficacy in other sclerodermoid diseases, imatinib mesylate is a promising new tool in the management of this challenging disease.

    View details for DOI 10.1111/j.1525-1470.2010.01301.x

    View details for Web of Science ID 000290381900017

    View details for PubMedID 21504445

  • Lipoatrophic Panniculitis Case Report and Review of the Literature ARCHIVES OF DERMATOLOGY Shen, L. Y., Edmonson, M. B., Williams, G. P., Gottam, C. C., Hinshaw, M. A., Teng, J. M. 2010; 146 (8): 877-881


    Lipoatrophic panniculitis (LP) is a rare disease of childhood characterized by eruption of tender erythematous nodules and plaques followed by circumferential bands of lipoatrophy often seen on the arms and legs. This condition has also been known as lipophagic panniculitis of childhood, annular atrophy of the ankles, and partial lipodystrophy.A previously healthy 8-year-old boy was evaluated for tender, raised plaques on the ankles, which progressed to circumferential atrophy of the distal lower extremities. Biopsy specimen analysis revealed a dense mixed infiltrate extending into the subcutaneous tissue as well as lipophages within the fatty lobules. A diagnosis of LP was made, and the patient began treatment with prednisone and hydroxychloroquine. Methotrexate was added later to the regimen as a steroid-sparing agent, and the dose was increased over the course of 3 months, by which time the cutaneous disease progression was nearly halted. However, the patient continued to have lower leg pain with bone changes demonstrated on magnetic resonance imaging.We report this case and review of the literature to call attention to the clinical features of LP and its association with skeletal changes. Our patient's response to combination therapy is of interest and contributes to the limited literature about management of this disease.

    View details for Web of Science ID 000281249700010

    View details for PubMedID 20713820

  • Topical Rapamycin A Novel Approach to Facial Angiofibromas in Tuberous Sclerosis ARCHIVES OF DERMATOLOGY Haemel, A. K., O'Brian, A. L., Teng, J. M. 2010; 146 (7): 715-718

    View details for Web of Science ID 000280088100002

    View details for PubMedID 20644030

  • Rapid Improvement in Digital Ischemia and Acral Contracture in a Collodion Baby Treated With Topical Tazarotene JOURNAL OF DRUGS IN DERMATOLOGY Liu, R. H., Becker, B., Gunkel, J., Teng, J. 2010; 9 (6): 713-716


    Collodion baby is a rare congenital disorder whereby affected infants are born encased in a thick, taut, shiny, translucent membrane. The majority of babies with collodion membrane have associated disorders, most commonly nonbullous congenital ichthyosiform erythroderma and lamellar ichthyosis. The authors report a case of collodion baby with rare complication of acral contracture, ischemia and nail dystrophy. Topical treatment with tazarotene 0.1% gel resulted in rapid improvement. The patient developed normal nail plates and full motor function in both hands and feet following treatment. To the authors' knowledge, this is the first report demonstrating the benefit of topical tazarotene for management of this rare condition in a neonate.

    View details for Web of Science ID 000278572400022

    View details for PubMedID 20645539

  • Mohs Surgical Excision of a Granular Cell Tumor with Plexiform Features on the Arm of a 7-Year-Old Child DERMATOLOGIC SURGERY Youssef, S. M., Hinshaw, M., Longley, B. J., Snow, S., Teng, J. M. 2010; 36 (4): 546-550
  • Sweet's panniculitis associated with metastatic breast cancer JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY Teng, J. M., Draper, B. K., Boyd, A. S. 2007; 56 (2): S61-S62

    View details for DOI 10.1016/j.jaad.2006.05.023

    View details for Web of Science ID 000243982300023

    View details for PubMedID 17224394

  • CD2-mediated activation of the Tec-family tyrosine kinase ITK is controlled by proline-rich stretch-4 of the CD2 cytoplasmic tail INTERNATIONAL IMMUNOLOGY King, P. D., Sadra, A., Teng, J. M., Bell, G. M., DuPont, B. 1998; 10 (7): 1009-1016


    Ligation of the CD2 co-stimulatory receptor on human T lymphocytes induces tyrosine phosphorylation and activation of the Tec-family tyrosine kinase, ITK. To examine whether any of several proline-rich (PR) stretches of the CD2 cytoplasmic tail are necessary for ITK activation we introduced wild-type and mutated versions of rat CD2, each missing at least one PR stretch of the tail, into human Jurkat T leukemia cells. The influence of cytoplasmic tail mutations was then studied following stimulation of transfectants with the rat CD2 mAb pair, OX54/OX55. As predicted, wild-type rat CD2 was able to activate ITK in Jurkat cells. In addition, a truncation mutant, lacking the most membrane-distal PR stretch, PR6, was able to activate ITK. By contrast, all other studied truncation mutants, each of which is missing at least PR4-PR6, were unable to induce ITK activation. Of deletion mutants, deletion of the membrane-proximal PR stretches, PR1-PR3, did not impair rat CD2-mediated ITK activation. However, additional deletion of PR4 from a tail missing PR1 and PR2, deletion of PR2 and PR4, and deletion of PR4 alone from rat CD2 abrogated an ability to activate ITK. Thus, these results identify PR4 as an element of the CD2 tail that is required for activation of ITK. Furthermore, we show that, unlike wild-type rat CD2, PR4-deleted rat CD2 is unable to induce IL-2 secretion from Jurkat cells. This is consistent with the view that PR4-mediated activation of ITK is important for downstream signaling events induced by CD2 co-stimulation.

    View details for Web of Science ID 000074974300017

    View details for PubMedID 9701039

  • Analysis of CD28 cytoplasmic tail tyrosine residues as regulators and substrates for the protein tyrosine kinases, EMT and LCK JOURNAL OF IMMUNOLOGY King, P. D., Sadra, A., Teng, J. M., Liu, X. R., Han, A., Selvakumar, A., August, A., DuPont, B. 1997; 158 (2): 580-590


    The CD28 cell surface receptor provides an important costimulatory signal for T cells necessary for their response to Ag. Early events in CD28 signaling include recruitment and activation of phosphatidylinositol 3-kinase (PI3-kinase) and activation of the protein tyrosine kinases (PTKs), LCK and EMT. Recruitment and activation of PI3-kinase is known to be dependent upon phosphorylation of tyrosine 173 of the CD28 cytoplasmic tail contained within a YMNM motif. By contrast, little is known of which residues of the CD28 tail, including tyrosines, are required for the activation of PTKs. To address this we studied the ability of truncation mutants and tyrosine to phenylalanine substitution mutants of the CD28 cytoplasmic tail to activate LCK and EMT in Jurkat T leukemia cells. Our results indicate that 1) activation of EMT is partially dependent upon tyrosine 173 of the CD28 tail, although it does not require PI3-kinase activation; 2) activation of LCK is independent of CD28 cytoplasmic tail tyrosine residues; and 3) elements sufficient for the activation of both kinases are contained within the first half of the tail. In addition we studied the CD28 tail as a substrate for both PTKs in in vitro kinase assays. We demonstrate that EMT can phosphorylate all four tyrosines of the CD28 tail, in contrast to LCK, which phosphorylates only tyrosine 173. Together with evidence that in vivo, tyrosines other than tyrosine 173 become phosphorylated following CD28 stimulation, this finding suggests that, like LCK, one function of EMT during CD28 signaling is phosphorylation of the receptor.

    View details for Web of Science ID A1997WC63800007

    View details for PubMedID 8992971

  • The Tec family tyrosine kinases BTK and ITK in lymphocyte development and activation 40th Symposium of the Alfred-Benzon-Foundation on HLA and Disease - the Molecular Basis DuPont, B., August, A., Teng, J. M., Sadra, A., King, P. D. MUNKSGAARD. 1997: 284–298
  • Phosphorylation of each of the distal three tyrosines of the CD28 cytoplasmic tail is required for CD28-induced T cell IL-2 secretion TISSUE ANTIGENS Teng, J. M., King, P. D., Sadra, A., Liu, X., Han, A., Selvakumar, A., August, A., DuPont, B. 1996; 48 (4-I): 255-264
  • Phosphorylation of each of the distal three tyrosines of the CD28 cytoplasmic tail is required for CD28-induced T cell IL-2 secretion. Tissue antigens Teng, J. M., King, P. D., Sadra, A., Liu, X., Han, A., Selvakumar, A., August, A., DuPont, B. 1996; 48 (4): 255-264


    Signaling by the CD28 T cell costimulatory receptor is known to involve recruitment and activation of phosphatidylinositol 3-kinase (PI3-kinase) which is dependent upon phosphorylation of tyrosine 173 of the CD28 cytoplasmic tail, present in a YMNM motif. However, whether this phosphorylation is required for CD28 costimulation and whether or not phosphorylation of any of the other three tyrosines of the CD28 cytoplasmic tail (tyrosines 188, 191 and 200) is also important for CD28 induced responses is unclear. To address this we examined the ability of chimeric receptors, consisting of the extracellular plus transmembrane membrane domain of human CD8 alpha linked to different mutated human CD28 cytoplasmic tails, to induce IL-2 secretion in Jurkat T leukemia cells in the presence of PMA and ionomycin. A receptor in which tyrosine 173 of the CD28 tail was mutated to phenylalanine was able to induce IL-2. By contrast, receptors which contained single tyrosine 188, 191 or 200 to phenylalanine substitutions were unable to induce IL-2. These results imply that in this system phosphorylation of tyrosine 173 and hence activation of PI3-kinase is not required for CD28 induced IL-2 secretion. Further, they imply that phosphorylation of each of tyrosines 188, 191 and 200 is necessary for this response. Despite an apparent requirement for phosphorylation of all three of these tyrosines, however, receptors which contain tyrosine only at positions 191 or 200 and a truncated receptor which does not contain tyrosine 200 induce normal IL-2. These last findings, therefore, illustrate the complexity of CD28 mediated activation signals.

    View details for PubMedID 8946678

  • CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C JOURNAL OF IMMUNOLOGY Teng, J. M., Liu, X. R., Mills, G. B., DuPont, B. 1996; 156 (9): 3222-3232


    The human leukemic cell line YT displays spontaneous cytotoxicity against CD80+ and/or CD86+ and ICAM-1+ target cells. In this work, we report that CD28-mediated cytotoxicity of YT involves tyrosine phosphorylation and activation of phosphatidylinositol (PI) 3-kinase, the Tec kinase Itk/Emt, and protein kinase C (PKC). YT mediates lysis of CD80+/CD86+ B lymphoblastoid cell lines and the murine mastocytoma p815 transfected with CD80 or CD86. The lysis was inhibited by two different Pi 3-kinase inhibitors, wortmannin and LY294002. The PKC inhibitors calphostin C and bisindolylmaleimide GF109203X also abolished YT-mediated cytotoxicity. Furthermore, exocytosis of cytolytic effector molecules was also inhibited by PI 3-kinase inhibitors and PKC inhibitors. PMA together with Ionomycin did not induce granule exocytosis or cytotoxicity by YT cells. Treatment of YT cells with PMA for up to 20 h, which depleted PMA-responsive PKC isoforms, had no effect on the CD28-mediated cytotoxicity. This cytotoxicity displayed by PMA-treated YT cells, however, could still be inhibited by Pi 3-kinase inhibitors and PKC inhibitors. Taken together, these results are consistent with a model in which activation of CD28 and LFA-1 induces tyrosine phosphorylation of the CD28 cytoplasmic domain, recruitment and activation of PI 3-kinase, as well as the Tec kinase Itk/Emt, and the activation of PMA-nonresponsive PKC isoenzymes. Activation of PI 3-kinase and PMA-nonresponsive PKC isoenzymes is shown to be involved directly in cytolytic granule release by YT cells.

    View details for Web of Science ID A1996UF74200018

    View details for PubMedID 8617944



    An examination of the crystal structure of HLA-A2.1 reveals two classes of residues on the class I MHC molecule that could affect CTL recognition: (1) those predicted to interact with the TCR directly; and (2) those that interact with bound peptides. To examine the role of individual TCR contacting residues, as well as residues not predicted to interact with bound peptide or the TCR, a panel of 28 HLA-A2 variants that differ from each other by a single amino acid substitution in either the alpha 1- or alpha 2-domain was utilized. Peptide titration, time course and cold target inhibition analysis of these targets showed that only the substitution of position 62 in the alpha 1-domain had a significant effect on recognition of the MHC-peptide complex by influenza matrix protein M1 (57-68) peptide-specific, HLA-A2.1-restricted CTL. In contrast, substitutions at positions 154, 162 and 163 in the alpha 2-domain abolished recognition by the same CTL. Additionally, substitutions at position 138 in the alpha 2-domain and positions 107 and 127 on the loops connecting the beta-strand in the alpha 2-domain were recognized in a more efficient, heteroclitic fashion. Overall, there was no direct correlation between the level of peptide binding to the variants and the level of T cell recognition of the variants. These results indicate that residues in the alpha 2-domain may be more important than residues in the alpha 1-domain in controlling TCR binding to the class I MHC molecule and suggest that the "footprint" of the TCR may be more extensive than previously predicted and encompass a broad region that extends beyond the alpha 2-helix. These findings also imply that the class I MHC molecule may exist in a "tipped" orientation on the cell surface during T cell recognition.

    View details for Web of Science ID A1994NK03000005

    View details for PubMedID 8183283



    Most of the polymorphic residues in class I MHC molecules are concentrated in the alpha 1- and alpha 2-domains with their side chains pointing towards the antigen peptide site. Previous crystal structure analysis revealed six pockets inside the peptide-binding groove and the "extra" electron density in some of the pockets indicated that the pockets are involved in direct peptide binding. In order to investigate the functional role of individual positions from each pocket in antigen presentation, 37 HLA-A2 variants with single amino acid substitution in the peptide-binding groove were generated and used to analyse the specificity of influenza A virus matrix peptide-specific, HLA-A2-restricted CTL. The ability to present peptide by each variant was studied in detail by peptide titration, cold target inhibition, time course and limiting dilution analysis. The direct effect on peptide binding by these substitutions was determined by cell surface class I MHC molecule reconstitution analysis. The results demonstrated that each of the six peptide binding pockets plays a role in T cell recognition. Substitutions introduced into pocket F had less effect on CTL recognition than substitutions introduced in other pockets. With the exception of Tyr substitution for Phe9, single amino acid substitutions in the peptide-binding groove had only minor effects on peptide binding. Therefore, the impact of the substitutions in altering the epitopes recognized by CTL seems to be mediated through an alteration in the conformation of the bound peptide.

    View details for Web of Science ID A1994NK03000006

    View details for PubMedID 8183284